Alto Neuroscience (ANRO) Other Non-Current Liabilities (2023)

Alto Neuroscience (ANRO) reported Other Non-Current Liabilities of $1.4 million for Q4 2023, down 3.43% sequentially from $1.4 million in Q3 2023.

Alto Neuroscience (ANRO) Other Non-Current Liabilities (2023) Analysis & Trends

Alto Neuroscience (ANRO) has 1 years of Other Non-Current Liabilities data on file, last reported at $1.4 million in Q4 2023.

For the quarter ending Q4 2023, Other Non-Current Liabilities changed N/A year-over-year to $1.4 million; the trailing twelve-month figure through Dec 2023 stood at $1.4 million (changed N/A YoY), and the FY2023 full-year result was $1.4 million, changed N/A from the prior year.
Other Non-Current Liabilities declined to $1.4 million in Q4 2023, from $1.4 million in the prior quarter.
In the past five years, Other Non-Current Liabilities ranged from a high of $1.7 million in Q1 2023 to a low of $1.4 million in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Alto Neuroscience	881.86 Mn	881.86 Mn	-

Download Data